Improving care for Black patients with gastrointestinal cancer
EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastrointestinal Cancer.
This study is trying to improve cancer care for Black patients with gastrointestinal cancers by ensuring they get the right tests and treatments while helping us understand the challenges they face.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Case Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Cleveland, Ohio) |
| Trial ID | NCT06263088 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the quality of care for Black patients diagnosed with various types of gastrointestinal cancer, including anal, colon, rectal, and esophageal cancers. It focuses on ensuring appropriate biomarker testing and evidence-based treatment recommendations through a tumor board. Participants will receive standard-of-care treatment while contributing to a better understanding of disparities in cancer care among Black individuals. The study seeks to address the treatment gap and improve outcomes for this underserved population.
Who should consider this trial
Good fit: Ideal candidates are Black adults aged 18 and older who have been newly diagnosed with gastrointestinal cancer.
Not a fit: Patients who are not Black or those who do not have a diagnosis of gastrointestinal cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment outcomes and reduced disparities in care for Black patients with gastrointestinal cancer.
How similar studies have performed: While there is ongoing research addressing disparities in cancer care, this specific approach focusing on Black patients with gastrointestinal cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult ≥ 18 years old. 2. Newly diagnosed Black GI cancer participants irrespective of stage. Eligible tumor types include anal carcinoma, rectal cancer, colon cancer, small bowel cancer, appendix carcinoma, hepatobiliary cancer, pancreatic cancer, gastroesophageal cancer, gastrointestinal neuroendocrine tumors, and gastrointestinal stromal tumor. 3. Patient able and willing to comply with study procedures 4. The patient is able to understand and willing to sign and date the written informed consent form at the screening visit. Exclusion Criteria: * NONE
Where this trial is running
Cleveland, Ohio
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Sakti Chakrabarti, MD — University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
- Study coordinator: Sakti Chakrabarti, MD
- Email: sakti.chakrabarti@uhhospitals.org
- Phone: 216-844-3951
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.